Abstract | Purpose: Methods: Participants were randomly assigned 1:1 to receive 3 monthly IVZ (1.25 mg/0.05 mL) or IVB (1.25 mg/0.05 mL) followed by the pro-re- nata protocol for persistent or recurrent macular edema. The primary outcomes were best-corrected visual acuity and central subfield thickness. An interim analysis was planned when half of the participants completed the follow-up. Results: Twenty-four participants were recruited. At 6 months, mean best-corrected visual acuity in the IVB and IVZ groups improved from 1.23 ± 0.64 to 0.76 ± 0.56 logMAR (p = 0.003) and from 1.13 ± 0.59 to 0.53 ± 0.26 logMAR (p = 0.003), respectively. The percentage of visual improvement and reduction in central subfield thickness in the IVZ group were insignificantly better than those in the IVB group (44.41 ± 26.72 vs 39.64 ± 24.22%; p = 0.65) and (51.94 ± 20.35 vs 45.78 ± 24.71%; p = 0.51), respectively. Although the mean number of injections was lower in the IVZ group (4.55 ± 1.29 vs 4.82 ±1.33), the difference was not statistically significant (p = 0.68). No ocular or systemic adverse events were observed. Conclusion: The interim analysis demonstrated that the visual and anatomical results of IVZ were insignificantly better than those of IVB at 6 months of follow-up. The results also showed that IVZ was non-inferior to IVB for anatomical improvement but inconclusive for visual improvement. Clinical Trial Registration: (identifier: TCTR20191205008).
|
Authors | Suthasinee Sinawat, Suthasinee Hemanak, Kwanchanok Chanthowong, Supat Sinawat, Yosanan Yospaiboon |
Journal | Clinical ophthalmology (Auckland, N.Z.)
(Clin Ophthalmol)
Vol. 17
Pg. 2719-2728
( 2023)
ISSN: 1177-5467 [Print] New Zealand |
PMID | 37743891
(Publication Type: Journal Article)
|
Copyright | © 2023 Sinawat et al. |